Microtubule Protein Drives Platinum Resistance in Ovarian Cancer

Although resistance has largely been understood through DNA repair pathways, these mechanisms do not fully explain why tumors return. Clarifying how cancer cells evade drug-induced stress is therefore critical to extending the benefit of existing regimens. Researchers now describe a microtubule-centered route to resistance and a strategy to resensitize tumors.

Michigan State University (East Lansing, MI, USA) researchers identified tubulin polymerization promoting protein 3 (TPPP3) as a microtubule dynamics regulator that enables ovarian cancer cells to withstand cisplatin or carboplatin. The work centers on cisplatin—first discovered at the university in 1965 and still described as a gold-standard therapy for ovarian and other cancers. The discovery outlines how elevated TPPP3 stabilizes the intracellular scaffolding that platinum drugs attempt to disrupt.

Beyond DNA damage, the study shows cisplatin also disrupts microtubules, and tumor cells adapt by rewiring the “tubulin code” to reinforce structural stability. TPPP3 mediates this adaptation by promoting tubulin polymerization, preserving the cytoskeletal network required for survival under chemotherapeutic stress. In laboratory models, removing TPPP3 restored cancer-cell sensitivity to cisplatin, while patients with lower TPPP3 levels lived longer and responded better to treatment.

The team is translating these insights into candidate strategies, including developing agents that target TPPP3 and evaluating whether the protein can serve as a biomarker to flag patients at risk for developing resistance. Planned studies will also assess how this mechanism interfaces with current chemotherapy combinations and whether it operates in additional cancer types. By shifting focus from DNA repair to cytoskeletal dynamics, the findings point to opportunities to strengthen established regimens rather than replace them.

Because microtubules are essential in many healthy tissues, the researchers note that the mechanism may also clarify common chemotherapy toxicities such as nerve damage, hair loss, and hearing loss. The study was published in Cell Reports on June 23, 2026. 

“This is about staying one step ahead of cancer. If scientists can understand how tumors adapt to survive treatment, we can start to block that process—making existing therapies more effective, more durable and ultimately more personalized for each patient,” said Sachi Horibata, assistant professor in the Precision Health Program and Department of Pharmacology and Toxicology at the MSU College of Human Medicine.

Related Links
MSU College of Human Medicine